NPHS2-6通过hsa-miR-1323/SMC1B轴驱动子宫状细胞癌 (CSCC) 的进展,以激活PI3K-Akt通路
Fen Li1, Yan Wang2, Mengke Wen1
1The Second Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, 789 Suzhou East Street, Urumqi, 830011, Xinjiang Province, China.
长非编码RNANPHS2-6通过调节miR-1323/SMC1B轴和激活PI3K/Akt路径,促进宫平细胞癌 (CSCC) 的进展. 针对这种途径为CSCC提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 长非编码RNAs (lncRNAs) 与各种癌症有关,包括宫平细胞癌 (CSCC).
- 了解CSCC中NPHS2-6等lncRNAs的特定作用对于开发向疗法至关重要.
研究的目的:
- 调查lncRNA NPHS2-6在宫平细胞癌 (CSCC) 进展中的作用和分子机制.
主要方法:
- 基因和蛋白质表达分析通过qRT-PCR和西方布洛特.
- 使用CCK-8,克隆形成,Transwell和伤口愈合试验评估的细胞增殖和转移.
- 通过生物信息学证实NPHS2-6,miR-1323和SMC1B之间的相互作用,双露西法酶记者和RNA拉下测定.
- 在体内验证使用裸体小鼠的皮下瘤模型.
主要成果:
- 在CSCC组织和细胞中,NPHS2-6的表达被上调.
- 在体内,NPHS2-6缺乏抑制了CSCC细胞生长,上皮-介质细胞转换 (EMT) 和异种移植瘤生长.
- NPHS2-6作为对 miR-1323 的竞争性内源RNA (ceRNA) 起作用,对SMC1B进行上调并激活PI3K/Akt通路,从而促进CSCC的瘤发生.
结论:
- 在NPHS2-6/miR-1323/SMC1B/PI3K/Akt信号通路加速CSCC的进展.
- 这一途径代表了部状细胞癌治疗的新型治疗标.
更多相关视频
07:26Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
相关概念视频
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Induced Pluripotent Stem Cells
Somatic...
The JAK-STAT Signaling Pathway
